Central Nervous System Therapeutics Market Size and Outlook 2031

Report Description

Forecast Period	2027-2031
Market Size (2025)	USD 115.21 Billion
CAGR (2026-2031)	7.96%
Fastest Growing Segment	Multiple Sclerosis
Largest Market	Asia Pacific
Market Size (2031)	USD 182.42 Billion

Market Overview

The Global Central Nervous System Therapeutics Market will grow from USD 115.21 Billion in 2025 to USD 182.42 Billion by 2031 at a 7.96% CAGR. Central Nervous System (CNS) therapeutics encompass pharmaceutical interventions designed to treat neurological and psychiatric disorders affecting the brain and spinal cord, including conditions such as Alzheimer’s disease and depression. The market is primarily propelled by the rapidly aging global population and the consequent surge in the prevalence of neurodegenerative diseases. Additionally, a growing worldwide recognition of mental health issues serves as a fundamental driver, creating sustained demand for effective pharmacological treatments.

However, the sector encounters a major impediment regarding the scientific complexity of developing drugs that effectively cross the blood-brain barrier, often leading to high clinical trial failure rates. This difficulty results in elevated development costs and prolonged timelines, potentially limiting market expansion. Underscoring the substantial financial commitment required to overcome such hurdles, according to the European Federation of Pharmaceutical Industries and Associations, in 2024, the research-based pharmaceutical industry invested an estimated €55 billion in research and development in Europe.

Key Market Drivers

The escalating global burden of neurological and psychiatric conditions stands as the primary catalyst propelling the Global Central Nervous System Therapeutics Market. As life expectancy increases, the accumulation of neurodegenerative risks intensifies, significantly expanding the patient pool that necessitates chronic pharmaceutical management. This demographic shift is further compounded by the widespread incidence of mental health disorders, which compels healthcare systems to prioritize effective intervention strategies and therapeutic accessibility. Illustrating the sheer scale of this medical challenge, according to the Institute for Health Metrics and Evaluation, March 2024, in a study published in 'The Lancet Neurology', over 3.4 billion individuals globally were estimated to be affected by neurological conditions, ranking them as the leading cause of ill health and disability worldwide. This vast patient base underpins an urgent, sustained demand for innovative medications capable of managing these complex disorders.

Simultaneously, the market is invigorated by a robust clinical pipeline and intensified capital allocation toward neuroscience research and development. Pharmaceutical entities are increasingly pursuing strategic acquisitions and partnerships to access novel mechanisms of action, particularly those addressing complex targets in schizophrenia and Alzheimer's disease. These investments are critical for overcoming historical barriers in CNS drug discovery, such as blood-brain barrier penetration, and for accelerating the commercialization of effective therapies. Exemplifying this trend of high-value consolidation, according to Bristol Myers Squibb, December 2023, in a press release regarding the acquisition of Karuna Therapeutics, the company agreed to acquire the neuroscience-focused biopharma firm for a total equity value of $14 billion to expand its portfolio in psychiatry. Underscoring the economic magnitude driving these investments, according to the Alzheimer's Association, in 2024, the total payments for caring for Americans with Alzheimer's and other dementias were projected to reach $360 billion, highlighting the immense commercial potential for disease-modifying treatments.

Download Free Sample Report

Key Market Challenges

The scientific complexity of developing drugs that effectively cross the blood-brain barrier constitutes a primary restraint on the global central nervous system therapeutics market. This biological mechanism acts as a selective filter, preventing many potential treatments from reaching their target sites in the brain. Consequently, pharmaceutical developers face exceptionally high attrition rates during clinical trials, as compounds often fail to demonstrate necessary efficacy or safety profiles in human subjects despite promising preclinical results. This high rate of failure forces companies to extend development timelines and increases the financial risk associated with neurological research projects.

The substantial resources required to mitigate these risks limit the number of viable market entrants and reduce overall profit margins for successful candidates. This capital-intensive environment creates barriers for smaller firms and slows the introduction of novel therapies. Underscoring the severity of these development hurdles, according to the Biotechnology Innovation Organization, in 2024, the clinical development success rate for new therapeutic candidates was approximately 6.7 percent. This low probability of approval discourages investment in the sector compared to other therapeutic areas with higher success rates, thereby hampering overall market expansion.

Key Market Trends

The Shift Toward Disease-Modifying Biologics for Neurodegenerative Disorders represents a fundamental transformation in the market, moving beyond symptomatic management to therapies that target the underlying pathology of conditions like Alzheimer's disease. This trend is currently dominated by the commercialization of anti-amyloid monoclonal antibodies, which have shown the ability to clear plaque deposits and slow cognitive decline. The successful market entry of these biologics is reshaping revenue models and encouraging substantial investment in infusion infrastructure and diagnostic pathways. Illustrating the rapid commercial uptake of these novel therapies, according to Eisai Co., Ltd., November 2024, in the 'Eisai updates Leqembi outlook for fiscal year 2024' press release, the company projects global revenue of JPY 42.5 billion for its Alzheimer's treatment Leqembi for the fiscal year ending March 2025, reflecting the growing adoption of disease-modifying agents.

Simultaneously, the Adoption of Artificial Intelligence for CNS Target Identification is accelerating the discovery of viable therapeutic candidates, addressing the historically high failure rates in neurological drug development. Pharmaceutical companies are increasingly partnering with AI-native firms to leverage machine learning algorithms that can analyze vast datasets of biological information, predicting drug-target interactions with greater precision than traditional methods. This integration of advanced computational tools allows for the rapid identification of novel pathways and the optimization of molecular structures before clinical testing begins. Highlighting the scale of capital flowing into this domain, according to Formation Bio, June 2024, in the 'Formation Bio Secures $372 Million Series D' press release, the company raised $372 million with participation from Sanofi to expand its AI-driven drug development capabilities, underscoring the industry's commitment to deploying artificial intelligence for more efficient therapeutic discovery.

Segmental Insights

The Multiple Sclerosis segment represents the fastest-growing category within the Global Central Nervous System Therapeutics Market, driven by the increasing introduction of novel disease-modifying therapies. This rapid expansion is supported by a surge in product approvals from regulatory bodies like the U.S. FDA, particularly for advanced monoclonal antibodies and oral biologics that offer improved efficacy. Additionally, heavy investment in research and development has strengthened the clinical pipeline, directly addressing the chronic nature of the condition. The combination of rising global prevalence and earlier diagnosis rates continues to elevate demand for effective long-term treatments, thereby sustaining the segment's accelerated market performance.

Regional Insights

Based on information from trusted market research, Asia Pacific dominates the Global Central Nervous System Therapeutics Market, driven by a rapidly expanding geriatric population and a high prevalence of neurological disorders in major economies like China and India. The region’s leadership is supported by aggressive government initiatives to modernize healthcare infrastructure and improve patient access to affordable treatments. Furthermore, the strong presence of generic drug manufacturers and favorable regulatory reforms facilitate widespread therapy adoption. These factors, alongside increasing investments from global pharmaceutical entities, establish Asia Pacific as the leading region in the global landscape.

Recent Developments

In September 2024, Bristol Myers Squibb announced that the U.S. Food and Drug Administration approved Cobenfy for the treatment of schizophrenia in adults. This regulatory milestone introduced the first new class of medicine for schizophrenia in several decades, offering a novel mechanism of action that targets cholinergic receptors rather than dopamine receptors. The launch addressed a critical gap in the central nervous system therapeutics market by providing an alternative for patients who may not respond well to traditional antipsychotic treatments. The approval was based on data from the EMERGENT clinical program, which established the drug's safety and efficacy profile.
In July 2024, Eli Lilly and Company received approval from the U.S. Food and Drug Administration for its new Alzheimer's disease treatment, Kisunla. This amyloid-targeting therapy was authorized for use in adult patients with early symptomatic Alzheimer's disease, including those with mild cognitive impairment and the mild dementia stage of the condition. The approval marked a significant advancement in the central nervous system therapeutics market, offering a treatment option that demonstrated the ability to slow cognitive and functional decline in clinical studies. The launch of this biologic represented a key addition to the company’s portfolio of neuroscience medicines.
In June 2024, Intra-Cellular Therapies announced positive topline results from a Phase 3 clinical trial evaluating lumateperone as an adjunctive therapy for major depressive disorder. The study demonstrated that the drug, administered once daily, achieved its primary endpoint by showing a statistically significant reduction in depression symptoms compared to placebo, as measured by the Montgomery-Åsberg Depression Rating Scale. These findings supported the efficacy of the treatment in a broader patient population within the central nervous system therapeutics market. The company planned to submit a supplemental new drug application to regulatory authorities based on this breakthrough research data.
In May 2024, Takeda Pharmaceutical Company entered into an exclusive, worldwide option and license agreement with AC Immune SA to collaborate on active immunotherapies for Alzheimer's disease. The partnership focused on ACI-24.060, an anti-amyloid beta active immunotherapy candidate designed to delay or slow the progression of the disease. Under the terms of the deal, AC Immune received an upfront payment of $100 million and became eligible for potential milestone payments totaling approximately $2.1 billion. This strategic collaboration aimed to leverage AC Immune’s proprietary platform and Takeda’s development capabilities to address the significant unmet needs in the central nervous system therapeutics market.

Key Market Players

Pfizer Inc.
Eli Lilly and Company
Johnson & Johnson Services, Inc.
Novartis International AG
Roche Holding AG
Bristol-Myers Squibb Company
Sanofi S.A.
GlaxoSmithKline plc
AbbVie Inc.
AstraZeneca plc

By Drug Class	By Application	By Route of Administration	By End User	By Distribution Channel	By Region
Multiple Sclerosis Antipsychotic Antiepileptics Analgesics & Anesthetics Anti-Parkinson Others	Neurodegenerative Diseases Mental Health and Trauma Neurovascular Diseases Infectious Diseases CNS Cancer Others	Oral Parenteral Others	Hospital Clinics Diagnostic Laboratories Others	Hospital Pharmacy Online Pharmacy Retail Pharmacy	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Central Nervous System Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Central Nervous System Therapeutics Market, By Drug Class:

Multiple Sclerosis
Antipsychotic
Antiepileptics
Analgesics & Anesthetics
Anti-Parkinson
Others

Central Nervous System Therapeutics Market, By Application:

Neurodegenerative Diseases
Mental Health and Trauma
Neurovascular Diseases
Infectious Diseases
CNS Cancer
Others

Central Nervous System Therapeutics Market, By Route of Administration:

Oral
Parenteral
Others

Central Nervous System Therapeutics Market, By End User:

Hospital
Clinics
Diagnostic Laboratories
Others

Central Nervous System Therapeutics Market, By Distribution Channel:

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Central Nervous System Therapeutics Market, By Region:

North America

United States
Canada
Mexico

Europe

France
United Kingdom
Italy
Germany
Spain

Asia Pacific

China
India
Japan
Australia
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Central Nervous System Therapeutics Market.

Available Customizations:

Global Central Nervous System Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Central Nervous System Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Central Nervous System Therapeutics Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Drug Class (Multiple Sclerosis, Antipsychotic, Antiepileptics, Analgesics & Anesthetics, Anti-Parkinson, Others)

5.2.2. By Application (Neurodegenerative Diseases, Mental Health and Trauma, Neurovascular Diseases, Infectious Diseases, CNS Cancer, Others)

5.2.3. By Route of Administration (Oral, Parenteral, Others)

5.2.4. By End User (Hospital, Clinics, Diagnostic Laboratories, Others)

5.2.5. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

5.2.6. By Region

5.2.7. By Company (2025)

5.3. Market Map

6. North America Central Nervous System Therapeutics Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Drug Class

6.2.2. By Application

6.2.3. By Route of Administration

6.2.4. By End User

6.2.5. By Distribution Channel

6.2.6. By Country

6.3. North America: Country Analysis

6.3.1. United States Central Nervous System Therapeutics Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Drug Class

6.3.1.2.2. By Application

6.3.1.2.3. By Route of Administration

6.3.1.2.4. By End User

6.3.1.2.5. By Distribution Channel

6.3.2. Canada Central Nervous System Therapeutics Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Drug Class

6.3.2.2.2. By Application

6.3.2.2.3. By Route of Administration

6.3.2.2.4. By End User

6.3.2.2.5. By Distribution Channel

6.3.3. Mexico Central Nervous System Therapeutics Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Drug Class

6.3.3.2.2. By Application

6.3.3.2.3. By Route of Administration

6.3.3.2.4. By End User

6.3.3.2.5. By Distribution Channel

7. Europe Central Nervous System Therapeutics Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Drug Class

7.2.2. By Application

7.2.3. By Route of Administration

7.2.4. By End User

7.2.5. By Distribution Channel

7.2.6. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Central Nervous System Therapeutics Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Drug Class

7.3.1.2.2. By Application

7.3.1.2.3. By Route of Administration

7.3.1.2.4. By End User

7.3.1.2.5. By Distribution Channel

7.3.2. France Central Nervous System Therapeutics Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Drug Class

7.3.2.2.2. By Application

7.3.2.2.3. By Route of Administration

7.3.2.2.4. By End User

7.3.2.2.5. By Distribution Channel

7.3.3. United Kingdom Central Nervous System Therapeutics Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Drug Class

7.3.3.2.2. By Application

7.3.3.2.3. By Route of Administration

7.3.3.2.4. By End User

7.3.3.2.5. By Distribution Channel

7.3.4. Italy Central Nervous System Therapeutics Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Drug Class

7.3.4.2.2. By Application

7.3.4.2.3. By Route of Administration

7.3.4.2.4. By End User

7.3.4.2.5. By Distribution Channel

7.3.5. Spain Central Nervous System Therapeutics Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Drug Class

7.3.5.2.2. By Application

7.3.5.2.3. By Route of Administration

7.3.5.2.4. By End User

7.3.5.2.5. By Distribution Channel

8. Asia Pacific Central Nervous System Therapeutics Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Drug Class

8.2.2. By Application

8.2.3. By Route of Administration

8.2.4. By End User

8.2.5. By Distribution Channel

8.2.6. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Central Nervous System Therapeutics Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Drug Class

8.3.1.2.2. By Application

8.3.1.2.3. By Route of Administration

8.3.1.2.4. By End User

8.3.1.2.5. By Distribution Channel

8.3.2. India Central Nervous System Therapeutics Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Drug Class

8.3.2.2.2. By Application

8.3.2.2.3. By Route of Administration

8.3.2.2.4. By End User

8.3.2.2.5. By Distribution Channel

8.3.3. Japan Central Nervous System Therapeutics Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Drug Class

8.3.3.2.2. By Application

8.3.3.2.3. By Route of Administration

8.3.3.2.4. By End User

8.3.3.2.5. By Distribution Channel

8.3.4. South Korea Central Nervous System Therapeutics Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Drug Class

8.3.4.2.2. By Application

8.3.4.2.3. By Route of Administration

8.3.4.2.4. By End User

8.3.4.2.5. By Distribution Channel

8.3.5. Australia Central Nervous System Therapeutics Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Drug Class

8.3.5.2.2. By Application

8.3.5.2.3. By Route of Administration

8.3.5.2.4. By End User

8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Central Nervous System Therapeutics Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Drug Class

9.2.2. By Application

9.2.3. By Route of Administration

9.2.4. By End User

9.2.5. By Distribution Channel

9.2.6. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Central Nervous System Therapeutics Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Drug Class

9.3.1.2.2. By Application

9.3.1.2.3. By Route of Administration

9.3.1.2.4. By End User

9.3.1.2.5. By Distribution Channel

9.3.2. UAE Central Nervous System Therapeutics Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Drug Class

9.3.2.2.2. By Application

9.3.2.2.3. By Route of Administration

9.3.2.2.4. By End User

9.3.2.2.5. By Distribution Channel

9.3.3. South Africa Central Nervous System Therapeutics Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Drug Class

9.3.3.2.2. By Application

9.3.3.2.3. By Route of Administration

9.3.3.2.4. By End User

9.3.3.2.5. By Distribution Channel

10. South America Central Nervous System Therapeutics Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Drug Class

10.2.2. By Application

10.2.3. By Route of Administration

10.2.4. By End User

10.2.5. By Distribution Channel

10.2.6. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Central Nervous System Therapeutics Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Drug Class

10.3.1.2.2. By Application

10.3.1.2.3. By Route of Administration

10.3.1.2.4. By End User

10.3.1.2.5. By Distribution Channel

10.3.2. Colombia Central Nervous System Therapeutics Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Drug Class

10.3.2.2.2. By Application

10.3.2.2.3. By Route of Administration

10.3.2.2.4. By End User

10.3.2.2.5. By Distribution Channel

10.3.3. Argentina Central Nervous System Therapeutics Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Drug Class

10.3.3.2.2. By Application

10.3.3.2.3. By Route of Administration

10.3.3.2.4. By End User

10.3.3.2.5. By Distribution Channel

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Central Nervous System Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Pfizer Inc.

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Eli Lilly and Company

15.3. Johnson & Johnson Services, Inc.

15.4. Novartis International AG

15.5. Roche Holding AG

15.6. Bristol-Myers Squibb Company

15.7. Sanofi S.A.

15.8. GlaxoSmithKline plc

15.9. AbbVie Inc.

15.10. AstraZeneca plc

16. Strategic Recommendations

17. About Us & Disclaimer

Figures and Tables

Figure 1: Global Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 2: Global Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 3: Global Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 4: Global Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 5: Global Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 6: Global Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 7: Global Central Nervous System Therapeutics Market Share, By Company, 2016-2026F

Figure 8: Global Central Nervous System Therapeutics Market Share, By Region, By Value, 2016-2026F

Figure 9: Global Central Nervous System Therapeutics Market Size, Market Map, By Value, 2016-2026F

Figure 10: North America Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 11: North America Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 12: North America Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 13: North America Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 14: North America Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 15: North America Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 16: North America Central Nervous System Therapeutics Market Share, By Country, By Value, 2016-2026F

Figure 17: United States Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 18: United States Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 19: United States Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 20: United States Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 21: United States Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 22: United States Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 23: Canada Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 24: Canada Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 25: Canada Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 26: Canada Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 27: Canada Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 28: Canada Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 29: Mexico Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 30: Mexico Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 31: Mexico Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 32: Mexico Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 33: Mexico Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 34: Mexico Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 35: Europe Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 36: Europe Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 37: Europe Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 38: Europe Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 39: Europe Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 40: Europe Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 41: Europe Central Nervous System Therapeutics Market Share, By Country, By Value, 2016-2026F

Figure 42: Germany Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 43: Germany Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 44: Germany Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 45: Germany Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 46: Germany Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 47: Germany Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 48: France Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 49: France Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 50: France Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 51: France Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 52: France Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 53: France Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 54: United Kingdom Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 55: United Kingdom Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 56: United Kingdom Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 57: United Kingdom Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 58: United Kingdom Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 59: United Kingdom Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 60: Italy Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 61: Italy Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 62: Italy Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 63: Italy Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 64: Italy Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 65: Italy Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 66: Spain Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 67: Spain Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 68: Spain Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 69: Spain Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 70: Spain Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 71: Spain Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 72: APAC Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 73: APAC Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 74: APAC Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 75: APAC Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 76: APAC Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 77: APAC Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 78: APAC Central Nervous System Therapeutics Market Share, By Country, By Value, 2016-2026F

Figure 79: China Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 80: China Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 81: China Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 82: China Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 83: China Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 84: China Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 85: Japan Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 86: Japan Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 87: Japan Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 88: Japan Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 89: Japan Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 90: Japan Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 91: India Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 92: India Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 93: India Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 94: India Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 95: India Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 96: India Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 97: South Korea Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 98: South Korea Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 99: South Korea Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 100: South Korea Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 101: South Korea Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 102: South Korea Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 103: Australia Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 104: Australia Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 105: Australia Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 106: Australia Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 107: Australia Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 108: Australia Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 109: South America Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 110: South America Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 111: South America Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 112: South America Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 113: South America Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 114: South America Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 115: South America Central Nervous System Therapeutics Market Share, By Country, By Value, 2016-2026F

Figure 116: Brazil Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 117: Brazil Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 118: Brazil Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 119: Brazil Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 120: Brazil Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 121: Brazil Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 122: Argentina Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 123: Argentina Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 124: Argentina Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 125: Argentina Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 126: Argentina Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 127: Argentina Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 128: Colombia Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 129: Colombia Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 130: Colombia Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 131: Colombia Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 132: Colombia Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 133: Colombia Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 134: MEA Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 135: MEA Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 136: MEA Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 137: MEA Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 138: MEA Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 139: MEA Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 140: MEA Central Nervous System Therapeutics Market Share, By Country, By Value, 2016-2026F

Figure 141: South Africa Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 142: South Africa Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 143: South Africa Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 144: South Africa Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 145: South Africa Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 146: South Africa Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 147: Saudi Arabia Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 148: Saudi Arabia Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 149: Saudi Arabia Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 150: Saudi Arabia Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 151: Saudi Arabia Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 152: Saudi Arabia Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Figure 153: UAE Central Nervous System Therapeutics Market Size, By Value (USD Million), 2016-2026F

Figure 154: UAE Central Nervous System Therapeutics Market Share, By Drug Class Type, By Value, 2016-2026F

Figure 155: UAE Central Nervous System Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F

Figure 156: UAE Central Nervous System Therapeutics Market Share, By Application, By Value, 2016-2026F

Figure 157: UAE Central Nervous System Therapeutics Market Share, By End User, By Value, 2016-2026F

Figure 158: UAE Central Nervous System Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Central Nervous System Therapeutics Market in 2025?

Which is the dominating region in the Global Central Nervous System Therapeutics Market?

Which is the fastest growing segment in the Global Central Nervous System Therapeutics Market?

What is the expected growth rate of the Global Central Nervous System Therapeutics Market?